Alcon Inc. (ALC.SW, SIX) earnings 24 Feb 2026: watch margins and guidance

ALC.SW stock faces a crucial earnings report after Alcon Inc. set results for 24 Feb 2026. We expect margins and U.S. Vision Care growth to drive the print. Alcon trades on the SIX in Switzerland at CHF 63.92 with a PE of 39.46 and EPS of 1.62. Ahead of the report, investors should watch revenue mix, surgical procedure volumes, and adoption of new contact lenses as near-term drivers.

ALC.SW stock: earnings timeline and market setup

Alcon will report results on 24 Feb 2026, after market hours. Traders closed today with Alcon at CHF 63.92, up CHF 0.88 on volume 965,580. The near-term market focus will be on organic sales, surgical backlog recovery, and any guidance updates.

ALC.SW stock: product news that could move revenue

Alcon launched TOTAL30 Multifocal for Astigmatism in the U.S. in February. Early adoption could lift Vision Care sales and recurring revenue. Read the company release for details Business Wire and the SEC filings for financial impact Seeking Alpha.

ALC.SW stock: fundamentals and valuation

Alcon trades at PE 39.46 on reported EPS 1.62. The company shows book value per share CHF 44.74 and free cash flow yield 3.92%. These metrics imply premium valuation versus some healthcare peers, reflecting stable cash flow and product pricing power.

ALC.SW stock: technicals and trading signals

Price closed CHF 63.92 with a 50-day average of CHF 62.90 and 200-day average CHF 65.60. RSI sits near 55.59, and Bollinger middle band is CHF 61.62. Volume today was 965,580, near the average 1,088,621, suggesting measured buying ahead of earnings.

ALC.SW stock: Meyka grade and analyst context

Meyka AI rates ALC.SW with a score out of 100: 74.45 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. The in-house grade balances Alcon’s cash flow strength against above-average valuation metrics.

ALC.SW stock: risks and catalysts into earnings

Key catalysts include U.S. vision-care sales, surgical procedure trends, and margin guidance. Major risks are slower adoption for premium contact lenses and pressure on surgical volumes. Watch management commentary on pricing and inventory in the quarter.

Final Thoughts

Key takeaways for ALC.SW stock before earnings: Alcon trades at CHF 63.92 on the SIX in Switzerland. The upcoming 24 Feb 2026 report should clarify margin direction and the early revenue impact from TOTAL30 Multifocal for Astigmatism. Meyka AI’s forecast model projects CHF 61.27 for the year, implying -4.17% from today’s price. For scenario planning we set a conservative price target CHF 58.00 (implied -9.29%) and a bullish target CHF 75.00 (implied +17.31%). These targets reflect surgical recovery sensitivity and Vision Care adoption. Forecasts are model-based projections and not guarantees. Use reported margins, procedure volumes, and guidance as the decisive signals, and consult Alcon filings for the full financial picture. For more data see our Alcon page at Meyka ALC.SW page. Meyka AI provides this data as an AI-powered market analysis platform and not as investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.